CEFTIN
LOE ApproachingNDAORALTABLET
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFTIN is an oral cephalosporin antibiotic approved in 1987 by GSK for bacterial infections. The drug is a broad-spectrum beta-lactam that inhibits bacterial cell wall synthesis. It treats a range of community-acquired infections across multiple body systems.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team focus likely shifting to cost management and niche indications rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEFTIN offers limited career acceleration opportunities given its LOE-approaching status and zero linked job openings. Working on this product typically involves defensive commercial strategies, cost management, and regulatory maintenance rather than high-visibility launches or innovation.
Brand ManagerMarket Access Manager
Worked on CEFTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.